Allogene Therapeutics Inc (NAS:ALLO)
$ 2.02 -0.12 (-5.61%) Market Cap: 448.70 Mil Enterprise Value: 252.75 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Allogene Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 05:05PM GMT
Release Date Price: $28.58 (+3.74%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

For the next session, I'm Matt Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly, before we get started, I have to read a disclosure statement. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures, or you can pick up a copy at the registration desk.

So with that, happy to have Allogene here with me. We have Eric and Susie. Eric's going to ask the questions because he has plenty of familiarity with doing it on his own, and I'm going to sit here and...

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

No. But so look, I think, maybe just to start out for everybody's benefit, I think a good place to start is, there have been lots of cell therapy companies out there, right? And -- but there's not -- progress with the allogeneic approach has been low

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot